Design and synthesis of aminothiazole based Hepatitis B Virus (HBV) capsid inhibitors was written by Pan, Ting;Ding, Yanchao;Wu, Liyang;Liang, Liting;He, Xin;Li, Qianwen;Bai, Chuan;Zhang, Hui. And the article was included in European Journal of Medicinal Chemistry in 2019.Related Products of 103-16-2 The following contents are mentioned in the article:
The capsid assembly is an essential step for Hepatitis B Virus (HBV) life cycle and is an important target for anti-HBV drug development. In this report, we identified a hit compound with aminothiazole structure by the high throughput screening (HTS) which inhibited the interaction of HBV capsid protein within the cells. The structure hopping and SAR studies of the hit compound afforded compound 79 with potent anti-HBV replication activity and good basic drug-like properties. The working mechanism studies showed that compound 79 could bind to the similar binding site of known HBV capsid inhibitor with heteroaryldihydropyrimidine (HAP) scaffold, through similar hydrophobic interactions but with a different hydrogen bond. This compound exerted potent inhibitory effect upon HBV production, either in cell culture or in mice with no obvious acute toxicity. We propose that further development of this compound could lead to novel potent anti-HBV inhibitors that target HBV capsid assembly. This study involved multiple reactions and reactants, such as 4-Benzyloxyphenol (cas: 103-16-2Related Products of 103-16-2).
4-Benzyloxyphenol (cas: 103-16-2) belongs to ethers. Carboxylic acid esters of low molecular weight are colourless, volatile liquids with pleasant odours, slightly soluble in water. Esters are more polar than ethers but less polar than alcohols. They participate in hydrogen bonds as hydrogen-bond acceptors, but cannot act as hydrogen-bond donors, unlike their parent alcohols. This ability to participate in hydrogen bonding confers some water-solubility.Related Products of 103-16-2
Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem